Drug name - Dymista

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration Jun, 2023

(8 months from now)

US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration Jun, 2023

(8 months from now)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids Aug, 2023

(10 months from now)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration Dec, 2023

(1 year, 2 months from now)

US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids Feb, 2024

(1 year, 4 months from now)

US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids Feb, 2026

(3 years from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids Aug, 2026

(3 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Treatment: Treatment of seasonal allergic rhinitis; Treatment of seasonal allergic rhinitis; treatment of allergic rhinitis, including seasonal allergic rhinitis; allergic rhinitis; treatment of symptoms of seasonal allergic rhinitis; relief of symptoms associated with seasonal allergic rhinitis

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.137MG/SPRAY;0.05MG/SPRAY SPRAY, METERED;NASAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.